Author: sHq_LoGiNz

VANCOUVER, British Columbia, JUNE 10, 2026, /3BL/ –DP World has successfully achieved Green Marine recertification across four of its Canadian terminals, reinforcing its commitment to environmental stewardship and continuous improvement across port operations.

The results build on DP World’s growing participation in the Green Marine program. In November 2024, the company expanded its membership to include terminals in Vancouver, Nanaimo, and Saint John. These additional terminals joined Prince Rupert, which has been Green Marine certified since 2013. This expansion marked a significant step in scaling a consistent, measurable approach to sustainability across DP World’s Canadian network.

David Bolduc, Green Marine International President and CEO, said: “DP World’s latest Green Marine results clearly demonstrate how a long-term, structured approach to environmental performance can deliver tangible gains across an entire terminal network. Seeing multiple facilities reach the highest levels in areas like air emissions and community impacts is a strong signal of leadership to the wider marine industry, and exactly the kind of continual improvement our program is designed to foster.”

Green Marine is a voluntary, third-party verified environmental certification program for ports, terminals, shipyards and ship owners in North America, with a similar framework in Europe. It also certifies participants in Australia. The program evaluates participants across a range of environmental performance indicators – including air emissions, community impacts, waste management, and spill prevention – using a five-level scale.

Level 1 represents regulatory compliance, while Level 5 reflects industry-leading performance and excellence.

Strong Results Across the Network

Across its terminals, DP World delivered consistent performance in core environmental indicators, with particularly strong results in air emissions and community impacts:

• Vancouver and Prince Rupert led the network, each achieving Level 5 – the highest possible rating – in both Air Emissions and Community Impacts, supported by Level 4 performance across community relations, environmental leadership, and spill prevention, and Level 3 in waste management.
• At Nanaimo, the terminal achieved Level 5 in Air Emissions and Level 4 in both Community Impacts and Community Relations, establishing a strong baseline for future progress, with opportunities identified in areas such as spill prevention and stormwater management.
• Meanwhile, Saint John demonstrated consistent, well-established performance, achieving Level 4 across four key indicators – Air Emissions, Community Impacts, Community Relations, and Environmental Leadership – alongside Level 3 in waste management and spill prevention.

Doug Smith, CEO of DP World in Canada, said: “Green Marine provides a clear, credible framework to measure and continuously improve our environmental performance across our operations. These results reflect the strength of our teams on the ground and our commitment to operating responsibly while delivering for our customers and partners. Just as importantly, strengthening environmental sustainability across our terminals enhances the long-term resilience of Canada’s supply chains – supporting the country’s ability to diversify trade, drive sustainable growth, and remain competitive in an evolving global market.”

Driving Performance Through Operational Excellence

The Green Marine verification process includes both a detailed document review and in-person site visits, ensuring that reported practices align closely with on-the-ground operations. Across all terminals, results are directly tied to day-to-day activities from emissions management and community engagement to waste handling and spill prevention.

Bronwyn Pountney, Environment Manager for DP World in Canada, said: “As with all Green Marine verifications, these results are a direct reflection of what happens day-to-day across our terminals. We’re proud of the progress we’ve made, particularly in areas like air emissions and community impacts, and we’re focused on building on this momentum to further strengthen our performance in the years ahead.”

By participating in Green Marine, DP World gains a structured framework to benchmark progress, set targets, and drive continuous improvement across its operations – ensuring sustainability remains embedded in every aspect of its business.

– END –

For more insights into how DP World is reshaping global trade, visit our website: www.dpworld.com

For media enquiries, please contact:

Melina Vissat, Head of Communications 
M: (+1) 704-605-6159 
E: melina.vissat@dpworld.com

About DP World

DP World is reshaping the future of global trade to improve lives everywhere. Operating across six continents with a team of over 125,000 employees, we combine global infrastructure and local expertise to deliver seamless supply chain solutions. From Ports and Terminals to Marine Services, Logistics and Technology, we leverage innovation to create better ways to trade, minimizing disruptions from the factory floor to the customer’s door.

In the Americas, DP World operates with a team of over 16,000 people across 12 countries, driving excellence through a robust network of 14 ports and terminals and more than 40 warehouses. By harnessing our global reach and local expertise, we simplify logistics, enhance operational performance, and redefine the boundaries of what’s possible in global trade.

WE MAKE TRADE FLOW.

ROCHESTER, Minn., June 10, 2026 /3BL/ – Urbaneer and the Well Living Lab recently hosted a networking event showcasing plans for the Home Innovation Lab (HIL), an innovative residential home designed to demonstrate how research, technology, and human-centered design can support healthier living environments and aging in place. The site will include a residential research environment focused on human-centered living as well as an experience center designed to evaluate emerging products and technologies in a real-world home setting.

Held at the Well Living Lab in downtown Rochester, Minnesota, in the heart of the Destination Medical Center (DMC) district, the event was planned in conjunction with DMC’s annual Real Estate & Investment Summit and welcomed developers, builders, healthcare leaders, researchers, and community stakeholders for conversations centered on the future of residential wellness and housing innovation.

Attendees explored the Home Innovation Lab renderings, educational displays, research insights, and interactive experiences highlighting how residential environments can better support health and well-being through evidence-based design. Key focus areas included indoor air quality, lighting, sleep, stress recovery, biophilic design, and technology-enabled solutions that support aging in place and long-term wellness.

“The Home Innovation Lab reflects the kind of forward-thinking collaboration that continues to position Rochester as a leader in innovation and as America’s City for Health,” said Patrick Seeb, Executive Director, DMC EDA. “As communities nationwide navigate evolving housing needs and demographic shifts, initiatives like this demonstrate how technology and cross-industry partnerships can help shape healthier homes and more resilient communities.”

“We are seeing a major shift in the market, with consumer demand rising fast for healthy homes, which we know can play a critical role supporting human health and well-being,” said Rachel Hodgdon, President and CEO, International WELL Building Institute. “Initiatives like the Home Innovation Lab — alongside the growing momentum behind WELL for residential — demonstrate how research, technology and thoughtful residential design can come together to support healthier living environments for people across every stage of life.”

Construction on the Home Innovation Lab is anticipated to begin in the fourth quarter of 2026, with the Lab expected to be fully operational by the second quarter of 2027.

# # #

About Urbaneer

Urbaneer is a wellness real estate and residential intelligence company focused on creating healthier, technology-enabled living environments that support comfort, safety, and well-being across all stages of life. With more than a decade of specialized expertise, Urbaneer has completed more than 30 residential projects across five states and continues to advance technology-driven approaches that support health and healthcare delivery within the home. For more information, visit urbaneerliving.com or contact Bruce Thompson, CEO, at bruce@urbaneerliving.com.

About the Well Living Lab

The Well Living Lab, founded in 2016 as a collaboration between Delos and Mayo Clinic, is the first research facility dedicated exclusively to studying the real-world impact of indoor environments on human health and well-being. To date, the Well Living Lab has completed 43 studies and generated 45 peer-reviewed publications, with formal academic affiliations including the University of Minnesota. For more information, visit welllivinglab.com or contact Barb Spurrier, Executive Director, at barbara.spurrier@delos.com.

Contact: Sarah Kelling, Director of Communications & Marketing, Well Living Lab

507.421.9864 | sarah.kelling@delos.com

Originally published on CVS Health Company Newsroom

WOONSOCKET, R.I., June 10, 2026 /3BL/ – CVS Health (NYSE: CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members— including the reintroduction of Zepbound® (tirzepatide) as a covered medication. These changes build on Caremark’s industry leading efforts as a pharmacy benefits manager to explore all potential avenues that help patients get FDA-approved weight management medications at an affordable cost. Plan sponsors that adopt CVS Caremark template formularies retain discretion to customize coverage for their members.

What changes is CVS Caremark making to its weight management drug coverage?

CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026, increasing access to GLP-1s at a more affordable price for plan sponsors who elect to provide coverage of those medications for their members. Additionally, effective June 1, 2026, CVS Caremark will remove the new-to-market block on Foundayo™(orforglipron), a new oral GLP-1 therapy, where approved for coverage by plans.

Over the past year, we’ve been actively driving change in the GLP-1 weight management space to help lower costs. Our approach has made a real difference, enabling us to now expand options while continuing to make progress on affordability.

We expect these changes to help drive increased savings in the weight management category – after a history of delivering double digit savings for our template formulary customers year over year – while expanding choice for our members.

Why is CVS Caremark adding Zepbound to their formulary?

Simply put, we achieved what our customers asked us for: deliver affordability and optionality in this important class.

“We’re creating access and options that would not have existed without our leadership in the market,” said Ed DeVaney, President, CVS Caremark. “We acted boldly through active engagement and negotiation with our drug manufacturer partners to tackle affordability and access for our customers and their members.”

What is CVS Caremark doing to bring down the cost of GLP-1s?

Over the past two years, high prices have put these therapies out of reach for the many people who could benefit from them. Last year, we took the initiative to drive engagement with manufacturers to bend the cost curve — similar to how we’ve helped improve affordability for drugs used for diabetes, high cholesterol, psoriasis, rheumatoid arthritis and many more. 

By acting early, we helped improve affordability and get ahead of a rapidly evolving GLP-1 pipeline. This past year, as this therapy class has continued to evolve, we worked with the manufacturers to secure a more affordable cost with positive results that allow us the flexibility to continue offering our customers more choice and access for their members.

What are the challenges with GLP-1 pricing?

While GLP-1s represent a major clinical advancement, the broad demand for a high-priced medicine creates a level of financial strain that is difficult to absorb at scale. As a result, many of our customers have made tough trade-offs, limiting coverage in order to maintain sustainable, balanced benefit programs. Ongoing collaboration with pharmaceutical companies is helping to make this in-demand drug class more accessible.

How was CVS Caremark able to lower the price of these weight management drugs?

As a pharmacy benefit manager, CVS Caremark is hired by businesses, big and small, health plans, unions, and government entities to negotiate the cost of medications included on formularies elected by plan sponsors that offer a benefit to their members. These negotiations have led us to deliver increased affordability and increased access to GLP-1s across the class.

What is a formulary and how does it impact patients?

A formulary is a list of prescription medications available under a health plan, managed with the support of a pharmacy benefit manager. CVS Caremark regularly evaluates formularies — which plan sponsors may adopt or customize based on the needs of their populations — to help support member access to clinically appropriate treatments as evaluated by an independent Pharmacy & Therapeutics committee while helping manage overall medication costs for customers and the members they serve. 

How is CVS Caremark supporting customers and members through these changes?

CVS Caremark will provide advanced communication and/or support to customers, consultants, providers and members to help ensure a smooth transition to covered therapies. These efforts include proactive outreach, educational resources, and clinical support programs. 

These formulary updates are one component of CVS Health’s ongoing efforts to address rising prescription drug costs and improve access to affordable medications for the millions of Americans it serves. 

About CVS Health

CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of March 31, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 88 million plan members. The Company also serves an estimated more than 37 million people through a broad range of health insurance products and related services. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, statements regarding the anticipated impact of the formulary changes on affordability, access, and member out-of-pocket costs, as well as statements regarding ongoing engagement with pharmaceutical manufacturers. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in CVS Health’s filings with the Securities and Exchange Commission, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and Current Reports on Form 8-K. You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health does not assume any duty to update or revise forward-looking statements except as required by law.

Media Contact:

Phil Blando
Phillip.Blando@cvshealth.com

Originally published on CVS Health Company Newsroom

WOONSOCKET, R.I., June 10, 2026 /3BL/ – CVS Health (NYSE: CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members— including the reintroduction of Zepbound® (tirzepatide) as a covered medication. These changes build on Caremark’s industry leading efforts as a pharmacy benefits manager to explore all potential avenues that help patients get FDA-approved weight management medications at an affordable cost. Plan sponsors that adopt CVS Caremark template formularies retain discretion to customize coverage for their members.

What changes is CVS Caremark making to its weight management drug coverage?

CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026, increasing access to GLP-1s at a more affordable price for plan sponsors who elect to provide coverage of those medications for their members. Additionally, effective June 1, 2026, CVS Caremark will remove the new-to-market block on Foundayo™(orforglipron), a new oral GLP-1 therapy, where approved for coverage by plans.

Over the past year, we’ve been actively driving change in the GLP-1 weight management space to help lower costs. Our approach has made a real difference, enabling us to now expand options while continuing to make progress on affordability.

We expect these changes to help drive increased savings in the weight management category – after a history of delivering double digit savings for our template formulary customers year over year – while expanding choice for our members.

Why is CVS Caremark adding Zepbound to their formulary?

Simply put, we achieved what our customers asked us for: deliver affordability and optionality in this important class.

“We’re creating access and options that would not have existed without our leadership in the market,” said Ed DeVaney, President, CVS Caremark. “We acted boldly through active engagement and negotiation with our drug manufacturer partners to tackle affordability and access for our customers and their members.”

What is CVS Caremark doing to bring down the cost of GLP-1s?

Over the past two years, high prices have put these therapies out of reach for the many people who could benefit from them. Last year, we took the initiative to drive engagement with manufacturers to bend the cost curve — similar to how we’ve helped improve affordability for drugs used for diabetes, high cholesterol, psoriasis, rheumatoid arthritis and many more. 

By acting early, we helped improve affordability and get ahead of a rapidly evolving GLP-1 pipeline. This past year, as this therapy class has continued to evolve, we worked with the manufacturers to secure a more affordable cost with positive results that allow us the flexibility to continue offering our customers more choice and access for their members.

What are the challenges with GLP-1 pricing?

While GLP-1s represent a major clinical advancement, the broad demand for a high-priced medicine creates a level of financial strain that is difficult to absorb at scale. As a result, many of our customers have made tough trade-offs, limiting coverage in order to maintain sustainable, balanced benefit programs. Ongoing collaboration with pharmaceutical companies is helping to make this in-demand drug class more accessible.

How was CVS Caremark able to lower the price of these weight management drugs?

As a pharmacy benefit manager, CVS Caremark is hired by businesses, big and small, health plans, unions, and government entities to negotiate the cost of medications included on formularies elected by plan sponsors that offer a benefit to their members. These negotiations have led us to deliver increased affordability and increased access to GLP-1s across the class.

What is a formulary and how does it impact patients?

A formulary is a list of prescription medications available under a health plan, managed with the support of a pharmacy benefit manager. CVS Caremark regularly evaluates formularies — which plan sponsors may adopt or customize based on the needs of their populations — to help support member access to clinically appropriate treatments as evaluated by an independent Pharmacy & Therapeutics committee while helping manage overall medication costs for customers and the members they serve. 

How is CVS Caremark supporting customers and members through these changes?

CVS Caremark will provide advanced communication and/or support to customers, consultants, providers and members to help ensure a smooth transition to covered therapies. These efforts include proactive outreach, educational resources, and clinical support programs. 

These formulary updates are one component of CVS Health’s ongoing efforts to address rising prescription drug costs and improve access to affordable medications for the millions of Americans it serves. 

About CVS Health

CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of March 31, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 88 million plan members. The Company also serves an estimated more than 37 million people through a broad range of health insurance products and related services. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, statements regarding the anticipated impact of the formulary changes on affordability, access, and member out-of-pocket costs, as well as statements regarding ongoing engagement with pharmaceutical manufacturers. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in CVS Health’s filings with the Securities and Exchange Commission, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and Current Reports on Form 8-K. You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health does not assume any duty to update or revise forward-looking statements except as required by law.

Media Contact:

Phil Blando
Phillip.Blando@cvshealth.com